Press Releases

AsiDNA™ Letter – No. 1

Ladies, Gentlemen and Shareholders, The clinical development of AsiDNA™ is well on its way and we would like to inform you regularly about the progress being made through a Letter dedicated to this first-in-class candidate. In this first issue, we go back to the fundamentals of the DNA Damage Response (DDR) therapeutic approach in oncology, which consists of fighting cancer…read more →

The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation

Paris (France), July 1st, 2019 – 7:00 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (hereinafter “Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced the publication of an initiation report by KEPLER CHEUVREUX, a…read more →

Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase

OX401 is the second candidate utilizing Onxeo’s proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation PARP inhibitor, designed to act on both the DNA Damage Response and the activation of immune response In vivo proof-of-concept results alone and in combination with cancer immunotherapies are expected by early Q4 2019   Paris (France), June 20, 2019…read more →

Onxeo renews its equity financing line with Nice & Green as part of the financing of its business and strategic activities

     The new financing line could represent a total of approximately €9 million over the upcoming 12 months, based on current stock price levels, extending the cash runway until Q3 2020      It may be suspended or terminated by Onxeo at any time      It provides Onxeo with the means to finance key activities over the next 12 months and…read more →

Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors

Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced the intratumoral activation of its DNA-PK target, confirming its mechanism of action The full results of the study will be presented at upcoming international scientific meetings Paris (France), May 28, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris,…read more →

Ordinary General Meeting of May 22, 2019

Renewal of the terms of office of Danièle Guyot-Caparros, Jean-Pierre Bizzari and Jean-Pierre Kinet Appointment of Danièle Guyot-Caparros as Chairman of the Board of Directors Paris (France), May 22, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA…read more →

Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy

DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in patients with solid tumors eligible to such treatments Initial results are expected in the second half of 2019   Paris (France), Mai 6, 2019 – 6:00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”),…read more →

Publication of the 2018 Registration Document

Paris (France), April 8, 2019 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, today announced the publication of the Company’s 2018 Registration Document. The 2018 Registration Document, filed with the French Market Authorities (Autorité des Marchés…read more →

Ordinary General Meeting on April 26, 2019

Paris (France), April 5, 2019 – 10 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced today that Onxeo’s shareholders are invited to attend the Company’s Ordinary General Meeting which is being held on Friday, April 26, 2019…read more →

Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting

Paris (France), March 25, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today provides details on the presentation of data from five studies supporting the…read more →

Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update

Clinical development of AsiDNA™ continues in phase 1 study DRIIV-1 Activity of AsiDNA™ demonstrated through the marked activation of its cellular targets enabling the determination of active doses and favorable tolerance profile Impending initiation of a phase 1b study in combination with platinum-based chemotherapy and paclitaxel; preliminary results expected before year-end 2019 New lead compound sourced from platON™ ready to…read more →

Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting

Paris (France), February 13, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced that results of five preclinical study supporting the differentiated profile of…read more →

Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor

Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical development of AsiDNA™ based on these predictive biomarkers of response   Paris (France), January 3, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development…read more →

Onxeo Announces its Financial Agenda for 2019

Paris (France), December 20, 2018 – 07:00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced its financial agenda for 2019. Event Date* Full-year 2018 results Tuesday, March 12, 2019 Shareholders’ general meeting…read more →

Onxeo receives EPO Intent-to-Grant Notice for new patent protecting AsiDNA™ in combination with any PARP inhibitor

Combination patent to be granted in Europe until 2036   Paris (France), December 18, 2018 – 8.30 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response (DDR) to fight resistant cancers, today announced having been notified by the European Patent Office…read more →